Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome
- PMID: 35057578
- PMCID: PMC8780869
- DOI: 10.3390/nu14020397
Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome
Abstract
(1) Background: Predictors of dietary treatment response in irritable bowel syndrome (IBS) remain understudied. We aimed to investigate predictors of symptom improvement during the low FODMAP and the traditional IBS diet for four weeks. (2) Methods: Baseline measures included faecal Dysbiosis Index, food diaries with daily energy and FODMAP intake, non-gastrointestinal (GI) somatic symptoms, GI-specific anxiety, and psychological distress. Outcomes were bloating, constipation, diarrhea, and pain symptom scores treated as continuous variables in linear mixed models. (3) Results: We included 33 and 34 patients on the low FODMAP and traditional IBS diet, respectively. Less severe dysbiosis and higher energy intake predicted better pain response to both diets. Less severe dysbiosis also predicted better constipation response to both diets. More severe psychological distress predicted worse bloating response to both diets. For the different outcomes, several differential predictors were identified, indicating that baseline factors could predict better improvement in one treatment arm, but worse improvement in the other treatment arm. (4) Conclusions: Psychological, nutritional, and microbial factors predict symptom improvement when following the low FODMAP and traditional IBS diet. Findings may help individualize dietary treatment in IBS.
Keywords: NICE guidelines; diet; disorders of the gut brain interaction; dysbiosis; functional gastrointestinal disorders; gastrointestinal symptoms; irritable bowel syndrome; low FODMAP diet; prediction; treatment response.
Conflict of interest statement
S.S. has served as advisory board member for Takeda and speaker for Viatris. H.T. has served as advisory board member/consultant for Almirall and Shire. L.V.O. is assistant research professor of the K.U. Leuven Special Research Fund (Bijzonder Onderzoeksfonds, BOF). J.T. has given scientific advice to Adare, AlfaWassermann, Allergan, Arena, Bayer, Christian Hansen, Clasado, Danone, Devintec, Falk, Grünenthal, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, Neurogastrx, Neutec, Novartis, Noventure, Nutricia, Shionogi, Shire, Takeda, Theravance, Tramedico, Truvion, Tsumura, Zealand, and Zeria Pharmaceutical; received research support from Shire, Sofar, and Tsumura; and served on the Speakers Bureau for Abbott, Allergan, AstraZeneca, Janssen, Kyowa Kirin, Menarini, Mylan, Novartis, Shire, Takeda, Truvion, and Zeria Pharmaceutical, all outside the submitted work. L.Ö. has received a financial support for research by Genetic Analysis AS, Biocodex, Danone Research and AstraZeneca and served as a consultant/advisory board member for Genetic Analysis AS, and as a speaker for Biocodex, Ferring Pharmaceuticals, Takeda, AbbVie, and Meda. M.S. has received grants and personal fees from Glycom and Danone Nutricia Research; personal fees from Ironwood, Menarini, Biocodex, Adnovate, Arena, Tillotts, Kyowa Kirin, Takeda, Alimentary Health, AlfaSigma, and the Falk Foundation; and grants from Genetic Analysis AS, outside the submitted work. The remaining authors disclose no conflicts. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. The authors declare no conflict of interest.
Figures
References
-
- Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160:99–114.e113. doi: 10.1053/j.gastro.2020.04.014. - DOI - PubMed
-
- Simrén M., Törnblom H., Palsson O.S., van Tilburg M.A.L., Van Oudenhove L., Tack J., Whitehead W.E. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: Consistent findings from five different patient cohorts. Gut. 2018;67:255–262. doi: 10.1136/gutjnl-2016-312361. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
